DC Field | Value | Language |
---|---|---|
dc.contributor.author | Beha, Marcel Janis | ko |
dc.contributor.author | Kim, Joo-Chan | ko |
dc.contributor.author | Im, San Hae | ko |
dc.contributor.author | Kim, Yunsu | ko |
dc.contributor.author | Yang, Seungju | ko |
dc.contributor.author | Lee, Juhee | ko |
dc.contributor.author | Nam, Yu Ri | ko |
dc.contributor.author | Lee, Haeshin | ko |
dc.contributor.author | Park, Hee-Sung | ko |
dc.contributor.author | Chung, Hyun Jung | ko |
dc.date.accessioned | 2023-10-06T02:00:53Z | - |
dc.date.available | 2023-10-06T02:00:53Z | - |
dc.date.created | 2023-08-07 | - |
dc.date.created | 2023-08-07 | - |
dc.date.issued | 2023-09 | - |
dc.identifier.citation | ADVANCED SCIENCE, v.10, no.27 | - |
dc.identifier.issn | 2198-3844 | - |
dc.identifier.uri | http://hdl.handle.net/10203/313060 | - |
dc.description.abstract | Bioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self-delivered nanomedicine platform based on bioorthogonal CRISPR/Cas9 conjugates, which can be armed with a chemotherapeutic drug for combinatorial therapy is introduced. It is demonstrated that multi-functionalized Cas9 with a drug and polymer can form self-condensed nanocomplexes, and induce significant gene editing upon delivery while avoiding the use of a conventional carrier formulation. It is shown that the nanomedicine platform can be applied for combinatorial therapy by incorporating the anti-cancer drug olaparib and targeting the RAD52 gene, leading to significant anti-tumor effects in BRCA-mutant cancer. The current development provides a versatile nanomedicine platform for combination treatment of human diseases such as cancer. | - |
dc.language | English | - |
dc.publisher | WILEY | - |
dc.title | Bioorthogonal CRISPR/Cas9-Drug Conjugate: A Combinatorial Nanomedicine Platform | - |
dc.type | Article | - |
dc.identifier.wosid | 001031571000001 | - |
dc.identifier.scopusid | 2-s2.0-85165483453 | - |
dc.type.rims | ART | - |
dc.citation.volume | 10 | - |
dc.citation.issue | 27 | - |
dc.citation.publicationname | ADVANCED SCIENCE | - |
dc.identifier.doi | 10.1002/advs.202302253 | - |
dc.contributor.localauthor | Lee, Haeshin | - |
dc.contributor.localauthor | Park, Hee-Sung | - |
dc.contributor.localauthor | Chung, Hyun Jung | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | bioorthogonal | - |
dc.subject.keywordAuthor | cancer therapy | - |
dc.subject.keywordAuthor | chemotherapeutic drugs | - |
dc.subject.keywordAuthor | combinatorial delivery | - |
dc.subject.keywordAuthor | CRISPR | - |
dc.subject.keywordAuthor | Cas9 | - |
dc.subject.keywordAuthor | gene editing | - |
dc.subject.keywordAuthor | nanomedicines | - |
dc.subject.keywordAuthor | unnatural amino acids | - |
dc.subject.keywordPlus | SYNTHETIC LETHALITY | - |
dc.subject.keywordPlus | NANOPARTICLE DELIVERY | - |
dc.subject.keywordPlus | GUIDE RNA | - |
dc.subject.keywordPlus | DONOR DNA | - |
dc.subject.keywordPlus | CAS9 | - |
dc.subject.keywordPlus | CRISPR-CAS9 | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | CANCER | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.